Principles and practice of monitoring immunosuppressive drugs

LaboratoriumsMedizin

Volumn 26, Issue 1-2, 2002, Pages 27-36

  Armstrong, Victor W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Azathioprine; Cyclosporine; Drug monitoring; Mycophenolic acid; Sirolimus; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DRUG METABOLITE; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE;

AREA UNDER THE CURVE; BONE MARROW TRANSPLANTATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW; THROMBOCYTOPENIA;

EID: 0036200563     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2002.005     Document Type: Review

References (69)

1. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
2. Consensus document: Therapeutic monitoring of tacrolimus (FK-506)
3. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel
4. Mycophenolate mofetil: A report of the consensus panel
5. The IFCC/IATDM-CT working group on immunosuppressive drug monitoring
6. Canadian Consensus Meeting on cyclosporine monitoring: Report of the consensus panel
7. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists task force
8. Thermospray high-performance liquid chromatography/mass spectrometric determination of cyclosporins
9. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood
10. Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood
11. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry
12. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
13. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
14. Evaluation of four automated methods for determination of whole blood cyclosporine concentrations
15. Cyclosporin A: Analytical methodology and factors affecting therapeutic drug monitoring
16. New approaches to cyclosporine monitoring raise further concerns about analytical techniques
17. Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral
18. Impact of absorption profiling on efficacy and safety, of cyclosporin therapy in transplant recipients
19. Two-hour cyclosporine concentration determination: An appropriate tool to monitor Neoral therapy
20. The temporal profile of calcineurin inhibition by cyclosporine in vivo
21. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry
22. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry
23. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus
24. Measurement of tacrolimus (FK506) and its metabolites: A review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies
25. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: Comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II)
26. Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function
27. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation
28. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group
29. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation
30. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients
31. From beach to bedside: History of the development of sirolimus
32. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
33. Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry
34. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry
35. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection
36. Clinical pharmacokinetics of sirolimus
37. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
38. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
39. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
40. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes
41. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit
42. Clinical pharmacokinetics of mycophenolate mofetil
43. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
44. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
45. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients
46. Coadministration of tacrolimus and mycophenolate mofetil (MMF) does not increase mycophenolic acid (MPA) exposure, but coadministration of cyclosporine and MMF inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure
47. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
48. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
49. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
50. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure
51. Monitoring of mycophenolic acid in pediatric renal transplant recipients
52. Limited sampling strategy for the determination, of mycophenolic acid area under the curve in pediatric kidney recipients
53. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
54. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
55. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?
56. Genotyping of the thiopurine methyltransferase deficiency mutations (TPMT*2-TPMT*7) with the light cycler: Examples for 3-color multiplexing, "two-color/shared" anchor, and fluorescence quenching hybridization probe assays based on thermodynamic nearest-neighbor probe designs
57. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties
58. Thiopurine S-methyl-transferase activity in human erythrocytes: A new HPLC method using 6-thioguanine as substrate
59. Inhibition of thiopurine S-methyl-transferase activity by impurities in commercially available substrates: A factor for differing results of TPMT measurements
60. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis
61. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity
62. High-performance liquid chromatographic determination of thiopurine metabolites of azathioprine in biological fluids
63. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC
64. Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methyl-thioguanine in humans
65. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine
66. Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation
67. Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
68. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
69. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease